Search by Drug Name or NDC
NDC 00074-2310-30 Rinvoq 30 mg/1 Details
Rinvoq 30 mg/1
Rinvoq is a ORAL TABLET, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is UPADACITINIB.
MedlinePlus Drug Summary
Upadacitinib is used alone or with other medications to treat rheumatoid arthritis (condition in which the body attacks its own joints causing pain, swelling, and loss of function) in people who are unable to take or have not responded well to one or more tumor necrosis factor (TNF) inhibitor medication(s). It is also used to treat psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin) in adults who are unable to take or did not respond to or tolerate one or more TNF inhibitor medication(s). Upadacitinib is also used to treat symptoms of eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in adults and children 12 years and older who cannot use other medications for their condition or whose eczema has not responded to other medications. It is also used to treat ulcerative colitis (a condition that causes swelling and sores in the lining of the colon [large intestine] and rectum) in adults who are unable to take or who did not respond to one or more TNF inhibitor medication(s). Upadacitinib is used to treat ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas, causing pain, swelling, and joint damage) in adults who are unable to take or who did not respond to one or more TNF inhibitor medication(s). Upadacitinib is in a class of medications called Janus kinase (JAK) inhibitors. It works by decreasing the activity of the immune system.
Related Packages: 00074-2310-30Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Upadacitinib
Product Information
NDC | 00074-2310 |
---|---|
Product ID | 0074-2310_b3ed4d84-05b2-41f8-9664-2e2fff13effc |
Associated GPIs | 66603072007530 |
GCN Sequence Number | 082927 |
GCN Sequence Number Description | upadacitinib TAB ER 24H 30 MG ORAL |
HIC3 | Z2Z |
HIC3 Description | JANUS KINASE (JAK) INHIBITORS |
GCN | 51719 |
HICL Sequence Number | 045955 |
HICL Sequence Number Description | UPADACITINIB |
Brand/Generic | Brand |
Proprietary Name | Rinvoq |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Upadacitinib |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET, EXTENDED RELEASE |
Route | ORAL |
Active Ingredient Strength | 30 |
Active Ingredient Units | mg/1 |
Substance Name | UPADACITINIB |
Labeler Name | AbbVie Inc. |
Pharmaceutical Class | Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA211675 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00074-2310-30 (00074231030)
NDC Package Code | 0074-2310-30 |
---|---|
Billing NDC | 00074231030 |
Package | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2310-30) |
Marketing Start Date | 2019-08-16 |
NDC Exclude Flag | N |
Pricing Information | N/A |